| dc.creator | Tsoucalas G., Chevallier J., Karamanou M., Papaioannou T., Sgantzos M., Androutsos G. | en |
| dc.date.accessioned | 2023-01-31T10:18:01Z | |
| dc.date.available | 2023-01-31T10:18:01Z | |
| dc.date.issued | 2016 | |
| dc.identifier | 10.2174/1381612822666160111124615 | |
| dc.identifier.issn | 13816128 | |
| dc.identifier.uri | http://hdl.handle.net/11615/80110 | |
| dc.description.abstract | Thrombosis is a well known phenomenon among physicians since antiquity. A variety of peculiar agents, such as leeches and bark, were used to prevent it. Hirudin was used during the 19th century. The next eon, heparin, strepokinase, urokinase, TPA, dicumarol, warfarin, aspirin, ticlopidine, Clopidogrel, SSHA and SP54 provoked huge advances in anticoagulation. During 21st century with the use of fondaparinux, dabigatran, rivaroxaban and Ticagrelor antithrombotic prevention and therapeutic interaction entered an era of medical challenges. Although the risk after a thrombotic episode is now highly reduced, blood clots still present damaging or even lethal consequences in human organisms and further research is strongly recommended. © 2016 Bentham Science Publishers. | en |
| dc.language.iso | en | en |
| dc.source | Current Pharmaceutical Design | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964240547&doi=10.2174%2f1381612822666160111124615&partnerID=40&md5=ce26ec0348affb209e8c2290b0210264 | |
| dc.subject | acetylsalicylic acid | en |
| dc.subject | anticoagulant agent | en |
| dc.subject | antithrombocytic agent | en |
| dc.subject | clopidogrel | en |
| dc.subject | dicoumarol | en |
| dc.subject | heparin | en |
| dc.subject | hirudin | en |
| dc.subject | pentosan polysulfate | en |
| dc.subject | streptokinase | en |
| dc.subject | ticagrelor | en |
| dc.subject | ticlopidine | en |
| dc.subject | urokinase | en |
| dc.subject | warfarin | en |
| dc.subject | anticoagulant agent | en |
| dc.subject | antithrombocytic agent | en |
| dc.subject | anticoagulation | en |
| dc.subject | Article | en |
| dc.subject | bleeding disorder | en |
| dc.subject | blood clotting | en |
| dc.subject | disease severity | en |
| dc.subject | drug acetylation | en |
| dc.subject | fibrinolysis | en |
| dc.subject | human | en |
| dc.subject | nonhuman | en |
| dc.subject | priority journal | en |
| dc.subject | thrombocyte function | en |
| dc.subject | thromboembolism | en |
| dc.subject | thrombosis | en |
| dc.subject | drug effects | en |
| dc.subject | history | en |
| dc.subject | thrombosis | en |
| dc.subject | Anticoagulants | en |
| dc.subject | Blood Coagulation | en |
| dc.subject | History, 19th Century | en |
| dc.subject | History, 20th Century | en |
| dc.subject | History, 21st Century | en |
| dc.subject | Humans | en |
| dc.subject | Platelet Aggregation Inhibitors | en |
| dc.subject | Thrombosis | en |
| dc.subject | Bentham Science Publishers B.V. | en |
| dc.title | Historical hallmarks of anticoagulation and antiplatelet agents | en |
| dc.type | journalArticle | en |